Article
DLL3 expression in large cell neuroendocrine carcinoma (LCNEC) and association with molecular subtypes and neuroendocrine profile.
Lung cancer (Amsterdam, Netherlands) - 1 Dec 2019
Hermans B C M, Derks J L, Thunnissen E, van Suylen R J, den Bakker M A, Groen H J M, Smit E F, Damhuis R A, van den Broek E C, Ruland A, Speel E J M, Dingemans A M C
Abstract excerpt
OBJECTIVES: For stage IV pulmonary large cell neuroendocrine carcinoma (LCNEC), the only therapeutic option is palliative chemotherapy. DLL3 is a new therapeutic target, which seems to be often expressed in SCLC and LCNEC. It has recently been reported that DLL3 mRNA expression is particularly upregulated in the LCNEC subgroup with STK11/KEAP1 and TP53 co-mutations, in contrast to lower expression levels in RB1...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.